A Message For Our Shareholders

Yesterday, Optimi Health announced an important MDMA and psilocybin supply agreement for Australians approved under the country’s Authorised Prescribers Scheme.

Our new long-term relationship with Mind Medicine Australia positions Optimi as the primary supplier to Australia’s newly regulated psychedelic market.

From day one, our goal has been to become the best end-to-end psychedelics manufacturer and formulator in the world. Over the last three years, we have drawn from our past experiences in our other successful business ventures to position Optimi as a leader in this emerging market. We will continue to apply that same work ethic in the years to come.

We’ve demonstrated our commitment to this objective by constructing the largest dedicated GMP psychedelics facility in the space, hiring top analytical chemists and scientists, and surrounding ourselves with an incredibly talented operations and management team that cares passionately about helping people.

Optimi is not reliant on contract manufacturing to source and supply any of its products approved under its Health Canada Dealer’s Licence. We are the manufacturer. Our business model of being a true end-to-end producer puts us in the position to lead the supply of medical-grade psychedelics throughout regulated jurisdictions. This advantage was instrumental in helping us build our network in the Australian psychedelics market.

Our signed Purchase Orders with Mind Medicine Australia will ensure that patients with treatment resistant post-traumatic stress disorder (PTSD) have access to medical grade GMP MDMA, and patients with treatment resistant depression have access to GMP encapsulated psilocybin as part of therapy through their authorized treating psychiatrists when rescheduling becomes effective on July 1, 2023.

From the first conversation we had with Mind Medicine Australia Chair, Peter Hunt, to the signing of the Purchase Order, we made it our mission to “fulfill a higher humanitarian purpose,” which meant providing a scalable and affordable product that would be accessible to all Australians.

As we enter the next phase of our existence, we would like to thank our shareholders for making this development possible. It is because of your patience, support, and belief from the very beginning, that we are now able to deliver on the promise of psychedelic medicines approved in regulated jurisdictions like Australia.

As new jurisdictions open and we further expand the scope of our production to meet demand, our position as a true end-to-end supplier will continue to ensure the same competitive advantage that has allowed us to secure this immediate primacy in the Australian market.

Optimi’s founders have been committed to heading and financing our operations. This remains the case as our journey to becoming the leading global supplier of GMP psychedelic substances is well and truly underway. Australia was the first step. It will not be the last.

We look forward to sharing more exciting news with you soon.

Thank you.

Dane, JJ, Bryan & Jacob




Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

Optimi Health Corp. is an end-to-end Canadian-based drug manufacturer and formulator licensed by Health Canada to produce and supply natural, GMP-grade psilocybin, synthetic psychedelic substances, and high-quality functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator and manufacturer in North America.


Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca


This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 9, 2023, and other continuous disclosure filings available under Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.